Incyte Corp. (INCY): Rasio rega marang pendapatan

Tandha merek Incyte Pharma (INCY)

Incyte Corporation (INCY) seeks to protect its hematology market share from generics by updating its drug formulas. Business growth is based on patents that enable the mass production of high-cost, high-margin medications. Revenues from Jakafi fund new developments in oncology and dermatology. The price/sales ratio trend visualizes the market valuation, where the 4.10 indicator determines the metric's value at this time.

INCY Multiplikator P/S Incyte Corporation (04.07.2022 - 13.11.2026)

Incyte Corp. (INCY) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
Rega bursa incyte.com|INCY - Bagan rega target
- data kapitalisasi bursa:
Nilai pasar Incyte Corp.|INCY - Nilai Total Perusahaan
- statistik nilai buku emiten:
Nilai Aset Bersih saben Saham Incyte|INCY - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas incyte.com|INCY - Gunggung Aset Perusahaan
- indikator beban kredit lan likuiditas emiten:
Utang marang Modal Incyte Corporation|INCY - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Incyte Pharma|INCY - Gunggung utang perusahaan|Utang marang modal buku Incyte Corp.|INCY - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Incyte|Likuiditas darurat incyte.com
- data bathi lan kelipatan valuasi:
INCY - Bathi resik perusahaan|Penghasilan resik sing dikarepake Incyte Corporation|INCY - Pangali P/E|Pangali Forward P/E Incyte Corp|INCY - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Incyte Corp.|INCY - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Incyte|INCY - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan incyte.com|INCY - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Incyte Corporation
- rincian pendapatan lan dodolan emiten:
INCY - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan incyte.com|INCY - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Incyte Corp.
Ringkesan analitik perusahaan:incyte.com
Produk seri Incyte Pharma

The P/S ratio determines the market value of one dollar of annual revenue, allowing for an assessment of the premium paid for a business regardless of current earnings. For Incyte Corporation (INCY), with its advanced R&D pipeline in JAK inhibitors and targeted therapy, this indicator reflects market expectations for future breakthroughs, making the historical P/S chart a key tool for analyzing the balance between innovative potential and asset valuation.

Perusahaan pesaing

HCM - Rega marang dodolan|Rasio rega marang pendapatan Nuvation Bio NUVB|Day One Biopharmaceuticals, Inc. - Rasio rega marang pendapatan|MNPR - Rasio rega marang pendapatan|Rega marang dodolan Inhibrx Corp|IMAB: Multiplikator P/S|Multiplikator rega marang pendapatan fennecpharma.com FENC|Kapitalisasi marang pendapatan HRTX|Rega marang dodolan Nuvectis Pharma Inc. NVCT|Kapitalisasi marang pendapatan CHRS (Coherus)|CRBP (Corbus Pharmaceuticals, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Cardiff Oncology - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan BYSI (beyondspringpharma.com)|BioAtla Corp - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan LIXT (Lixte Biotechnology Holdings Inc.)|CTXR: Multiplikator P/S|Rega marang dodolan Cellectar Corp (CLRB)|Rasio rega marang pendapatan BioLineRx Ltd.|CANF: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S APRE|Multiplikator P/S kaziatherapeutics.com (KZIA)|Rasio rega marang pendapatan Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Rasio rega marang dodolan|CMRX: Kapitalisasi marang pendapatan|Rega marang dodolan cyclacel.com|GTHX: Multiplikator P/S|KRON - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Kintara|Rasio kapitalisasi marang pendapatan ONCT (Oncternal Corp)|Multiplikator P/S PRTG